Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Asco | Vintage Vibes

GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

A study presented at ASCO 2026 and published June 10, 2026 found that GLP-1 receptor agonists (semaglutide, tirzepatide) are associated with a 30–47% reduction in breast cancer risk among women with diabetes or obesity. The effect may operate through mechanisms beyond weight loss. Here is the full analysis.

Medical Daily

Removing ‘invisibility cloaks’ and safely skipping chemo: new weapons in war on cancer shared at US conference

Drug that stops cancer cells hiding and a breakthrough pill for pancreatic cancer among highlights from Asco conference – but there were also notes of caution

The Guardian - UK

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development. John Oyler, BeOne’s co-founder, chairman and chief

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

MarketBeat

New blood test ‘offers genuine hope’ it can detect deadly cancers before symptoms appear

The test is ‘feasible at scale’ on the NHS, say researchers

The Independent UK

Galleri blood test ‘feasible at scale’ on NHS, say experts

The NHS-Galleri trial is exploring how well the blood test works within the health service, alongside screening, to pick up cancer cases earlier.

Evening Standard

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORENCE, Italy and NEW YORK, May 29, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present safety and preliminary efficacy for the…

AAP

Read news from The Economist, FT, and more,
with one subscription

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma. Chief Executive Officer Richard Pauls

MarketBeat

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re

MarketBeat

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

MarketBeat

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer. On an

MarketBeat

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company’s highlighted cervical and head and neck canc

MarketBeat

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MarketBeat

Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance. On th

MarketBeat

Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering. On the company’s fir

International Business Times

Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data

At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Results from the Ph1/2 BEXMAB Study."

The Independent UK

When women are having cancer symptoms dismissed, no wonder they turn to toxic ‘wellness’

LET’S UNPACK THAT: Cancer cases are on the rise in young people but misdiagnosis remains an issue, with everything from anxiety to menopause named as the culprit. Helen Coffey investigates why women in particular are more at risk of having their pain overlooked – and whether mistrust in medicine is…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double

Analysts are uber bullish on Actuate Therapeutics and PDS Biotechnology stocks for the next 12 months. Here’s why.

The Guardian - UK

Cancer experts warn of coffee enemas and juice diets amid rise in misinformation

Oncologists say patients rejecting proven treatments are dying needlessly because of increase in online ‘cures’

The Guardian - UK

Immunotherapy trial helps cancer patients with tumours live 40% longer

Experts praise groundbreaking results from therapy using genetically modified Car T-cells

The Independent UK

How a 1970s Chicano art group defied the mainstream and made history

“ASCO: Without Permission” is director Travis Gutiérrez Senger's latest documentary and executive produced by Gael Garcia Bernal and Diego Luna

The Guardian - UK

‘Enormous potential’: weight-loss drugs cut cancer risk by a fifth, research shows

Experts believe injections such as Wegovy could play a big role in preventing and treating the disease

The Guardian - UK

Cancer rates among under-50s in UK have risen 24% since 1995, figures show

Increase sharper than in any age group and is likely to be linked to soaring obesity levels, junk food and inactivity, say experts

The Independent UK

FDA approves first-of-its-kind new ‘bubble’ treatment for liver cancer

Histotripsy could cause less harmful side effects compared to radiation and chemotherapy, experts say

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Pennsylvania

132 stories

Macmillan Cancer Support

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.